5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serotonin O
Syndrome O
or O
Neuroleptic O
Malignant O
Syndrome O
( O
NMS O
) O
-like O
Reactions O
: O
The O
safety O
of O
coadministration O
with O
other O
serotonergic O
or O
antidopaminergic O
agents O
has O
not O
been O
established O
. O

Manage O
with O
immediate O
BELVIQ O
discontinuation O
and O
provide O
supportive O
treatment O
. O

( O
5.1 O
) O
* O
Valvular O
heart O
disease O
: O
If O
signs O
or O
symptoms O
develop O
consider O
BELVIQ O
discontinuation O
and O
evaluate O
the O
patient O
for O
possible O
valvulopathy O
. O

( O
5.2 O
) O
* O
Cognitive O
Impairment O
: O
May O
cause O
disturbances O
in O
attention O
or O
memory O
. O

Caution O
with O
use O
of O
hazardous O
machinery O
when O
starting O
BELVIQ O
treatment O
. O

( O
5.3 O
) O
* O
Psychiatric O
Disorders O
, O
including O
euphoria O
and O
dissociation O
: O
Do O
not O
exceed O
recommended O
dose O
of O
10 O
mg O
twice O
daily O
. O

( O
5.4 O
) O
* O
Monitor O
for O
depression O
or O
suicidal O
thoughts O
. O

Discontinue O
if O
symptoms O
develop O
. O

( O
5.4 O
) O
* O
Use O
of O
Antidiabetic O
Medications O
: O
weight O
loss O
may O
cause O
hypoglycemia O
. O

Monitor O
blood O
glucose O
. O

BELVIQ O
has O
not O
been O
studied O
in O
patients O
taking O
insulin O
. O

( O
5.5 O
) O
* O
Priapism O
: O
Patients O
should O
seek O
emergency O
treatment O
if O
an O
erection O
lasts O
> O
4 O
hours O
. O

Use O
BELVIQ O
with O
caution O
in O
patients O
predisposed O
to O
priapism O
. O

( O
5.6 O
) O
5.1 O
Serotonin O
Syndrome O
or O
Neuroleptic O
Malignant O
Syndrome O
( O
NMS O
) O
-like O
Reactions O
BELVIQ O
is O
a O
serotonergic O
drug O
. O

The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
or O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( O
NMS O
) O
-like O
reactions O
have O
been O
reported O
during O
use O
of O
serotonergic O
drugs O
, O
including O
, O
but O
not O
limited O
to O
, O
selective O
serotonin-norepinephrine O
reuptake O
inhibitors O
( O
SNRIs O
) O
and O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
, O
tricyclic O
antidepressants O
( O
TCAs O
) O
, O
bupropion O
, O
triptans O
, O
dietary O
supplements O
such O
as O
St O
. O
John O
's O
Wort O
and O
tryptophan O
, O
drugs O
that O
impair O
metabolism O
of O
serotonin O
( O
including O
monoamine O
oxidase O
inhibitors O
[ O
MAOIs O
] O
) O
, O
dextromethorphan O
, O
lithium O
, O
tramadol O
, O
antipsychotics O
or O
other O
dopamine O
antagonists O
, O
particularly O
when O
used O
in O
combination O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
aberrations I-NonOSE_AE
( O
e.g. O
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
in O
its O
most O
severe O
form O
, O
can O
resemble O
neuroleptic B-NonOSE_AE
malignant I-NonOSE_AE
syndrome I-NonOSE_AE
, O
which O
includes O
hyperthermia B-NonOSE_AE
, O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
with O
possible O
rapid B-NonOSE_AE
fluctuation I-NonOSE_AE
of I-NonOSE_AE
vital I-NonOSE_AE
signs I-NonOSE_AE
, O
and O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
or O
NMS B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
signs O
and O
symptoms O
. O

The O
safety O
of O
BELVIQ O
when O
coadministered O
with O
other O
serotonergic O
or O
antidopaminergic O
agents O
, O
including O
antipsychotics O
, O
or O
drugs O
that O
impair O
metabolism O
of O
serotonin O
, O
including O
MAOIs O
, O
has O
not O
been O
systematically O
evaluated O
and O
has O
not O
been O
established O
. O

If O
concomitant O
administration O
of O
BELVIQ O
with O
an O
agent O
that O
affects O
the O
serotonergic O
neurotransmitter O
system O
is O
clinically O
warranted O
, O
extreme O
caution O
and O
careful O
observation O
of O
the O
patient O
is O
advised O
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Treatment O
with O
BELVIQ O
and O
any O
concomitant O
serotonergic O
or O
antidopaminergic O
agents O
, O
including O
antipsychotics O
, O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

5.2 O
Valvular O
Heart O
Disease O
Regurgitant B-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
valvular I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
primarily O
affecting O
the O
mitral O
and/or O
aortic O
valves O
, O
has O
been O
reported O
in O
patients O
who O
took O
serotonergic O
drugs O
with O
5-HT2Breceptor O
agonist O
activity O
. O

The O
etiology O
of O
the O
regurgitant B-NonOSE_AE
valvular I-NonOSE_AE
disease I-NonOSE_AE
is O
thought O
to O
be O
activation O
of O
5-HT2Breceptors O
on O
cardiac O
interstitial O
cells O
. O

At O
therapeutic O
concentrations O
, O
BELVIQ O
is O
selective O
for O
5-HT2Creceptors O
as O
compared O
to O
5-HT2Breceptors O
. O

In O
clinical O
trials O
of O
1-year O
duration O
, O
2.4 O
% O
of O
patients O
receiving O
BELVIQ O
and O
2.0 O
% O
of O
patients O
receiving O
placebo O
developed O
echocardiographic O
criteria O
for O
valvular B-OSE_Labeled_AE
regurgitation I-OSE_Labeled_AE
at O
one O
year O
( O
mild O
or O
greater O
aortic B-OSE_Labeled_AE
regurgitation I-OSE_Labeled_AE
and/or O
moderate O
or O
greater O
mitral B-OSE_Labeled_AE
regurgitation I-OSE_Labeled_AE
) O
: O
none O
of O
these O
patients O
was O
symptomatic O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
see O
Clinical O
Pharmacology O
( O
12.1 O
) O
] O
. O

BELVIQ O
has O
not O
been O
studied O
in O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
or O
hemodynamically-significant O
valvular B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Preliminary O
data O
suggest O
that O
5HT2Breceptors O
may O
be O
overexpressed O
in O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
, O
Therefore O
, O
BELVIQ O
should O
be O
used O
with O
caution O
in O
patients O
with O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

BELVIQ O
should O
not O
be O
used O
in O
combination O
with O
serotonergic O
and O
dopaminergic O
drugs O
that O
are O
potent O
5-HT2Breceptor O
agonists O
and O
are O
known O
to O
increase O
the O
risk O
for O
cardiac B-NonOSE_AE
valvulopathy I-NonOSE_AE
( O
e.g. O
, O
cabergoline O
) O
. O

Patients O
who O
develop O
signs O
or O
symptoms O
of O
valvular B-NonOSE_AE
heart I-NonOSE_AE
disease I-NonOSE_AE
, O
including O
dyspnea B-NonOSE_AE
, O
dependent B-NonOSE_AE
edema I-NonOSE_AE
, O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
, O
or O
a O
new O
cardiac B-NonOSE_AE
murmur I-NonOSE_AE
while O
being O
treated O
with O
BELVIQ O
should O
be O
evaluated O
and O
discontinuation O
of O
BELVIQ O
should O
be O
considered O
. O

5.3 O
Cognitive O
Impairment O
In O
clinical O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
impairments B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
and O
memory O
were O
reported O
adverse O
reactions O
associated O
with O
1.9 O
% O
of O
patients O
treated O
with O
BELVIQ O
and O
0.5 O
% O
of O
patients O
treated O
with O
placebo O
, O
and O
led O
to O
discontinuation O
in O
0.3 O
% O
and O
0.1 O
% O
of O
these O
patients O
, O
respectively O
. O

Other O
reported O
adverse O
reactions O
associated O
with O
BELVIQ O
in O
clinical O
trials O
included O
confusion B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
and O
fatigue B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Since O
BELVIQ O
has O
the O
potential O
to O
impair B-OSE_Labeled_AE
cognitive I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
patients O
should O
be O
cautioned O
about O
operating O
hazardous O
machinery O
, O
including O
automobiles O
, O
until O
they O
are O
reasonably O
certain O
that O
BELVIQ O
therapy O
does O
not O
affect O
them O
adversely O
[ O
see O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.4 O
Psychiatric B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
Events O
of O
euphoria B-NonOSE_AE
, O
hallucination B-NonOSE_AE
, O
and O
dissociation B-NonOSE_AE
were O
seen O
with O
BELVIQ O
at O
supratherapeutic O
doses O
in O
short-term O
studies O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
, O
Drug O
Abuse O
and O
Dependence O
( O
9.2 O
) O
, O
and O
Overdosage O
( O
10 O
) O
] O
. O

In O
clinical O
trials O
of O
at O
least O
1-year O
in O
duration O
, O
6 O
patients O
( O
0.2 O
% O
) O
treated O
with O
BELVIQ O
developed O
euphoria B-OSE_Labeled_AE
, O
as O
compared O
with O
1 O
patient O
( O
< O
0.1 O
% O
) O
treated O
with O
placebo O
. O

Doses O
of O
BELVIQ O
should O
not O
exceed O
10 O
mg O
twice O
a O
day O
. O

Some O
drugs O
that O
target O
the O
central O
nervous O
system O
have O
been O
associated O
with O
depression B-NonOSE_AE
or O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
. O

Patients O
treated O
with O
BELVIQ O
should O
be O
monitored O
for O
the O
emergence O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
, O
and/or O
any O
unusual O
changes B-NonOSE_AE
in I-NonOSE_AE
mood I-NonOSE_AE
or O
behavior O
. O

Discontinue O
BELVIQ O
in O
patients O
who O
experience O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behaviors O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.5 O
Potential O
Risk O
of O
Hypoglycemia O
in O
Patients O
with O
Type O
2 O
Diabetes O
Mellitus O
on O
Anti-diabetic O
Therapy O
Weight B-NonOSE_AE
loss I-NonOSE_AE
may O
increase O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
treated O
with O
insulin O
and/or O
insulin O
secretagogues O
( O
e.g. O
, O
sulfonylureas O
) O
; O
hypoglycemia B-OSE_Labeled_AE
was O
observed O
in O
clinical O
trials O
with O
BELVIQ O
. O

BELVIQ O
has O
not O
been O
studied O
in O
combination O
with O
insulin O
. O

Measurement O
of O
blood O
glucose O
levels O
prior O
to O
starting O
BELVIQ O
and O
during O
BELVIQ O
treatment O
is O
recommended O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
. O

Decreases O
in O
medication O
doses O
for O
anti-diabetic O
medications O
which O
are O
non-glucose-dependent O
should O
be O
considered O
to O
mitigate O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
. O

If O
a O
patient O
develops O
hypoglycemia B-NonOSE_AE
after O
starting O
BELVIQ O
, O
appropriate O
changes O
should O
be O
made O
to O
the O
anti-diabetic O
drug O
regimen O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.6 O
Priapism O
Priapism B-OSE_Labeled_AE
( O
painful B-OSE_Labeled_AE
erections I-OSE_Labeled_AE
greater O
than O
6 O
hours O
in O
duration O
) O
is O
a O
potential O
effect O
of O
5-HT2Creceptor O
agonism O
. O

If O
not O
treated O
promptly O
, O
priapism B-NonOSE_AE
can O
result O
in O
irreversible O
damage B-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
erectile I-NonOSE_AE
tissue I-NonOSE_AE
. O

Men O
who O
have O
an O
erection B-NonOSE_AE
lasting I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
4 I-NonOSE_AE
hours I-NonOSE_AE
, O
whether O
painful O
or O
not O
, O
should O
immediately O
discontinue O
the O
drug O
and O
seek O
emergency O
medical O
attention O
. O

BELVIQ O
should O
be O
used O
with O
caution O
in O
men O
who O
have O
conditions O
that O
might O
predispose O
them O
to O
priapism B-NonOSE_AE
( O
e.g. O
, O
sickle B-NonOSE_AE
cell I-NonOSE_AE
anemia I-NonOSE_AE
, O
multiple B-NonOSE_AE
myeloma I-NonOSE_AE
, O
or O
leukemia B-NonOSE_AE
) O
, O
or O
in O
men O
with O
anatomical O
deformation O
of O
the O
penis B-NonOSE_AE
( O
e.g. O
, O
angulation I-NonOSE_AE
, O
cavernosal B-NonOSE_AE
fibrosis I-NonOSE_AE
, O
or O
Peyronie B-NonOSE_AE
' I-NonOSE_AE
s I-NonOSE_AE
disease I-NonOSE_AE
) O
. O

There O
is O
limited O
experience O
with O
the O
combination O
of O
BELVIQ O
and O
medication O
indicated O
for O
erectile B-NonOSE_AE
dysfunction I-NonOSE_AE
( O
e.g. O
, O
phosphodiesterase O
type O
5 O
inhibitors O
) O
. O

Therefore O
, O
the O
combination O
of O
BELVIQ O
and O
these O
medications O
should O
be O
used O
with O
caution O
. O

5.7 O
Heart O
Rate O
Decreases O
In O
clinical O
trials O
of O
at O
least O
1-year O
in O
duration O
, O
the O
mean B-NonOSE_AE
change I-NonOSE_AE
in I-NonOSE_AE
heart I-NonOSE_AE
rate I-NonOSE_AE
( O
HR O
) O
was O
- I-NonOSE_AE
1 O
. O

2 I-NonOSE_AE
beats O
per O
minute O
( O
bpm O
) O
in O
BELVIQ O
and O
-0 O
. I-NonOSE_AE
4 O
bpm O
in O
placebo-treated O
patients O
without O
diabetes O
and O
-2 O
. O

0 I-NonOSE_AE
beats I-NonOSE_AE
per I-NonOSE_AE
minute I-NonOSE_AE
( I-NonOSE_AE
bpm I-NonOSE_AE
) O
in O
BELVIQ O
and O
-0.4 O
bpm O
in O
placebo-treated O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
. O

The O
incidence O
of O
HR B-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
bpm I-OSE_Labeled_AE
was O
5.3 O
% O
in O
BELVIQ O
and O
3.2 O
% O
in O
placebo-treated O
patients O
without O
diabetes O
and O
3.6 O
% O
in O
BELVIQ O
and O
2.0 O
% O
in O
placebo-treated O
patients O
with O
type O
2 O
diabetes O
. O

In O
the O
combined O
population O
, O
adverse O
reactions O
of O
bradycardia B-OSE_Labeled_AE
occurred O
in O
0.3 O
% O
of O
BELVIQ O
and O
0.1 O
% O
of O
placebo-treated O
patients O
. O

Use O
with O
caution O
in O
patients O
with O
bradycardia B-NonOSE_AE
or O
a O
history O
of O
heart B-NonOSE_AE
block I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
first I-NonOSE_AE
degree I-NonOSE_AE
. O

5.8 O
Hematological B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
In O
clinical O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
adverse O
reactions O
of O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
( O
including O
leukopenia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
decreased B-OSE_Labeled_AE
white I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
) O
were O
reported O
in O
0.4 O
% O
of O
patients O
treated O
with O
BELVIQ O
as O
compared O
to O
0.2 O
% O
of O
patients O
treated O
with O
placebo O
. O

Adverse O
reactions O
of O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
red I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
( O
including O
anemia B-OSE_Labeled_AE
and O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
and O
hematocrit O
) O
were O
reported O
by O
1.3 O
% O
of O
patients O
treated O
with O
BELVIQ O
as O
compared O
to O
1.2 O
% O
treated O
with O
placebo O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Consider O
periodic O
monitoring O
of O
complete O
blood O
count O
during O
treatment O
with O
BELVIQ O
. O

5.9 O
Prolactin O
Elevation O
Lorcaserin O
moderately O
elevates B-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

In O
a O
subset O
of O
placebo-controlled O
clinical O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
greater O
than O
the O
upper O
limit O
of O
normal O
, O
two O
times O
the O
upper O
limit O
of O
normal O
, O
and O
five O
times O
the O
upper O
limit O
of O
normal O
, O
measured O
both O
before O
and O
2 O
hours O
after O
dosing O
, O
occurred O
in O
6.7 O
% O
, O
1.7 O
% O
, O
and O
0.1 O
% O
of O
BELVIQ-treated O
patients O
and O
4.8 O
% O
, O
0.8 O
% O
, O
and O
0.0 O
% O
of O
placebo-treated O
patients O
, O
respectively O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Prolactin O
should O
be O
measured O
when O
symptoms O
and O
signs O
of O
prolactin B-NonOSE_AE
excess I-NonOSE_AE
are O
suspected O
( O
e.g. O
, O
galactorrhea B-NonOSE_AE
, O
gynecomastia B-NonOSE_AE
) O
. O

There O
was O
one O
patient O
treated O
with O
BELVIQ O
who O
developed O
a O
prolactinoma B-OSE_Labeled_AE
during O
the O
trial O
. O

The O
relationship O
of O
BELVIQ O
to O
the O
prolactinoma B-NonOSE_AE
in O
this O
patient O
is O
unknown O
. O

5.10 O
Pulmonary O
Hypertension O
Certain O
centrally-acting O
weight O
loss O
agents O
that O
act O
on O
the O
serotonin O
system O
have O
been O
associated O
with O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
a O
rare O
but O
lethal O
disease O
. O

Because O
of O
the O
low O
incidence O
of O
this O
disease O
, O
the O
clinical O
trial O
experience O
with O
BELVIQ O
is O
inadequate O
to O
determine O
if O
BELVIQ O
increases O
the O
risk O
for O
pulmonary B-NonOSE_AE
hypertension I-NonOSE_AE
. O

